JP2022544688A5 - - Google Patents
Info
- Publication number
- JP2022544688A5 JP2022544688A5 JP2022509707A JP2022509707A JP2022544688A5 JP 2022544688 A5 JP2022544688 A5 JP 2022544688A5 JP 2022509707 A JP2022509707 A JP 2022509707A JP 2022509707 A JP2022509707 A JP 2022509707A JP 2022544688 A5 JP2022544688 A5 JP 2022544688A5
- Authority
- JP
- Japan
- Prior art keywords
- targeted
- trans
- transsplicing
- splicing
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888210P | 2019-08-16 | 2019-08-16 | |
| US62/888,210 | 2019-08-16 | ||
| US202062985633P | 2020-03-05 | 2020-03-05 | |
| US62/985,633 | 2020-03-05 | ||
| PCT/US2020/046523 WO2021034717A1 (en) | 2019-08-16 | 2020-08-14 | Targeted trans-splicing using crispr/cas13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544688A JP2022544688A (ja) | 2022-10-20 |
| JP2022544688A5 true JP2022544688A5 (https=) | 2023-08-22 |
Family
ID=72291120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509707A Pending JP2022544688A (ja) | 2019-08-16 | 2020-08-14 | Ｃｒｉｓｐｒ／ｃａｓ１３を使用する標的化トランススプライシング |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11767528B2 (https=) |
| EP (1) | EP4013873A1 (https=) |
| JP (1) | JP2022544688A (https=) |
| KR (1) | KR20220044811A (https=) |
| CN (1) | CN115023499A (https=) |
| AU (1) | AU2020333667A1 (https=) |
| CA (1) | CA3150747A1 (https=) |
| WO (1) | WO2021034717A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4277987A4 (en) * | 2021-02-25 | 2025-07-16 | Univ Duke | COMPOSITIONS AND METHODS FOR TRANSCRIPTOME ENGINEERING |
| WO2022187524A1 (en) * | 2021-03-05 | 2022-09-09 | The Jackson Laboratory | Multiplex rna targeting |
| WO2022266849A1 (zh) * | 2021-06-22 | 2022-12-29 | 中国科学院脑科学与智能技术卓越创新中心 | 新型CRISPR-Cas13蛋白的筛选及其应用 |
| EP4141112B1 (en) * | 2021-07-08 | 2025-06-11 | Korea Advanced Institute of Science and Technology | Rna expression regulation or editing method through activity control of cas13 protein |
| AU2022337146A1 (en) | 2021-09-03 | 2024-03-14 | Tacit Therapeutics, Inc. | Rna editing via recruitment of spliceosome components |
| AU2022343271A1 (en) * | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Recruitment in trans of gene editing system components |
| EP4404953A4 (en) * | 2021-09-21 | 2025-09-24 | Univ Johns Hopkins | MRNA REGULATORY THERAPY FOR THE TREATMENT OF HAPLOINSUFFICIENCY DISORDERS |
| US20240409920A1 (en) * | 2021-10-15 | 2024-12-12 | The Broad Institute, Inc. | Rna-guided trans-splicing of rna |
| EP4522758A4 (en) | 2022-05-13 | 2026-05-06 | Ascidian Therapeutics Inc | Abca4 trans-splicing molecules |
| CA3265828A1 (en) * | 2022-08-25 | 2024-02-29 | Massachusetts Institute Of Technology | PROGRAMMABLE RNA WRITING USING CRISPR EFFECTORS AND TRANS-SPLICING MODELS |
| WO2024112957A1 (en) | 2022-11-23 | 2024-05-30 | Amber Bio Inc. | Gene-modifying endonucleases |
| US20250151704A1 (en) * | 2023-11-10 | 2025-05-15 | Joseph Fenton Lawler | Trans-splicing methods and compositions for generation of single sex offspring |
| WO2026068725A1 (en) * | 2024-09-26 | 2026-04-02 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Synthetic transfer vehicles for delivering rna to cells |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| AU698739B2 (en) | 1995-06-06 | 1998-11-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
| US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
| GB0024550D0 (https=) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| EP2151248A1 (en) * | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| WO2011148194A1 (en) | 2010-05-28 | 2011-12-01 | Oxford Biomedica (Uk) Ltd | Delivery of lentiviral vectors to the brain |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
| SG2014012207A (en) * | 2011-08-12 | 2014-05-29 | Virxsys Corp | Compositions and methods for inducing apoptosis |
| WO2014110509A1 (en) * | 2013-01-14 | 2014-07-17 | Cellecta, Inc. | Methods and compositions for single cell expression profiling |
| US20190330620A1 (en) | 2016-10-14 | 2019-10-31 | Emendobio Inc. | Rna compositions for genome editing |
| EP3617311B1 (en) * | 2017-03-30 | 2024-11-20 | Kyoto University | Method for inducing exon skipping by genome editing |
| US10476825B2 (en) | 2017-08-22 | 2019-11-12 | Salk Institue for Biological Studies | RNA targeting methods and compositions |
-
2020
- 2020-08-14 CN CN202080058066.XA patent/CN115023499A/zh active Pending
- 2020-08-14 JP JP2022509707A patent/JP2022544688A/ja active Pending
- 2020-08-14 US US16/994,230 patent/US11767528B2/en active Active
- 2020-08-14 WO PCT/US2020/046523 patent/WO2021034717A1/en not_active Ceased
- 2020-08-14 AU AU2020333667A patent/AU2020333667A1/en not_active Abandoned
- 2020-08-14 CA CA3150747A patent/CA3150747A1/en active Pending
- 2020-08-14 KR KR1020227008026A patent/KR20220044811A/ko not_active Ceased
- 2020-08-14 EP EP20764510.2A patent/EP4013873A1/en active Pending
-
2023
- 2023-08-15 US US18/449,850 patent/US12297433B2/en active Active
-
2025
- 2025-04-07 US US19/171,510 patent/US20250236872A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544688A5 (https=) | ||
| US12006508B2 (en) | Methods and products for expressing proteins in cells | |
| Ryu et al. | Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy | |
| JP7550057B2 (ja) | ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法 | |
| EP3110454B1 (en) | Methods and compositions for nuclease-mediated targeted integration | |
| CN109689677B (zh) | 用于基因组编辑分子的细胞内递送的肽和纳米颗粒 | |
| Sun et al. | Synthesis and evaluation of pH-sensitive multifunctional lipids for efficient delivery of CRISPR/Cas9 in gene editing | |
| TW202113074A (zh) | 工程化之ｃａｓｘ系統 | |
| Meneghini et al. | Delivery platforms for CRISPR/Cas9 genome editing of glial cells in the central nervous system | |
| CN119487051A (zh) | Aav衣壳变体及其用途 | |
| WO2017091512A1 (en) | Methods and compositions for engineering immunity | |
| Soltani Dehnavi et al. | Changing fate: reprogramming cells via engineered nanoscale delivery materials | |
| AU2024234874A1 (en) | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents | |
| AU2025200686A1 (en) | Nucleic acid molecules containing spacers and methods of use thereof | |
| WO2018106782A1 (en) | Methods and compositions for enhancing functional myelin production | |
| IL323636A (en) | Repressor fusion protein systems | |
| WO2025174765A1 (en) | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents | |
| Kim et al. | Integration of adeno-associated virus-derived peptides into nonviral vectors to synergistically enhance cellular transfection | |
| AU2024351960A1 (en) | Novel nucleus targeting signal peptides and uses thereof | |
| Hamidieh et al. | The Control and Trust of CRISPR/Cas9 Genome Altering for Clinical Application with Gene Treatment and Treatment of Hereditary Diseases | |
| WO2025072816A2 (en) | Endogenous nucleus targeting signal peptides and uses thereof | |
| CN118660722A (zh) | 用于递送多核苷酸的组合物 | |
| AU2024370469A1 (en) | Novel lysosome targeting signal peptides and uses thereof | |
| WO2025096676A1 (en) | Novel lysosome targeting signal peptides and uses thereof | |
| WO2025080721A2 (en) | Endogenous cell membrane targeting signal peptides and uses thereof |